Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
By
WATCH LIVE
Plain bagel done well. Pleasantly substantive.
Summary
A new experimental pill called daraxonrasib has shown promising results in extending survival for patients with advanced pancreatic cancer. The drug blocks a mutated protein (KRAS) that drives tumor growth in over 90% of pancreatic cancer cases. In clinical trials, patients taking the daily pill lived a median of 13.2 months compared to 6.7 months for those on chemotherapy — nearly doubling survival time — with fewer severe side effects. While not a cure, researchers describe it as a significant step forward for one of the deadliest cancers.
Key quotes
· 2 pulledWhile not curing the cancer, it is a very large step forward.
The drug blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·5h ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·3mo ago